![1Globe Capital LLC (Sinovac Biotech Ltd. "SVA" stock) Investors Class Action Lawsuit Image](https://thebrios.com/wp-content/uploads/2022/08/1globe-capital-llc-sinovac-biotech-ltd-sva-stock-investors-class-action-lawsuit-300x229.jpg)
Payoneer Global Inc. (PAYO)
Whether directors and officers of Payoneer Global Inc. (PAYO) breached their fiduciary duties to the company and its shareholders.
Investigation
07/20/2021
Initial Lawsuit
12/14/2021
Lawsuit Progression
05/20/2022
This investigation concerns Sleep Number’s statements about the impact of supply constraints on its net sales and top and bottom line results.
This post is open for investors to gather facts, and findings and track their exposure to related lawsuits. We invite investors and shareholders to contribute to this investigation for their own benefit, add events to the factual timeline below and vote on events’ pertinence.
A lawsuit was subsequently filed. We will update this post as it unfolds.
07/20/2021
Sleep Number reports its Q2 2021 financial results, generally missing consensus estimates. CEO Shelly Ibach explained that “near-term supply constraints limited delivered net sales in June and July.”
During a conference call to discuss the results, executives explained that the company absorbed “the inflationary impact of a global supply chain that remains challenged by labor and material shortages.” Chief financial officer (CFO) David Callen further explained that “demand has temporarily exceeded supply” and “component shortages limited output from two third tier suppliers affecting [the company’s] deliveries in June and July.” He also added that “COVID-driven labor shortages had a tier one supplier, which have now been resolved, delayed their installation of additional production lines and will constrain [the company’s] delivery upside through Q3.”
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$97.78 | $112.24 | $-14.46 | -12.88% |
A Sleep Number Corporation investor filed a securities class action on behalf of all purchasers of Sleep Number common stock (SNBR) between February 18, 2021, and July 20, 2021, inclusive.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors:
(a) that Sleep Number had suffered a severe disruption in its supply chain for foam as a result of Winter Storm Uri;
(b) that Sleep Number did not have in place the supply chain flexibility, redundancies and fail-safes, as had been represented to investors, sufficient to offset the foam supply disruption caused by Winter Storm Uri;
(c) that, because foam was a necessary component for Sleep Number’s production of its primary mattress products, Sleep Number’s ability to timely fulfill customer orders had been materially impaired;
(d) that, as a result of (a)-(c) above, Sleep Number was unable to meet surging customer demand for the company’s products; and
(e) that, as a result of (a)-(d) above, Sleep Number had been forced to delay mattress shipments to end consumers, pushing millions of dollars’ worth of sales into subsequent quarters and negatively impacting the company’s financial results.
05/20/2022
The court issued an order appointing the lead plaintiff and lead counsel.
Whether directors and officers of Payoneer Global Inc. (PAYO) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of LegalZoom.com, Inc. (LZ) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Inari Medical, Inc. (NARI) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Builders FirstSource, Inc. (BLDR) breached their fiduciary duties to the company and its shareholders.
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Whether directors and officers of Kewaunee Scientific Corporation (KEQU) breached their fiduciary duties to the company and its shareholders.